Czas trwania erekcji: nowe ilościowe kryterium oceny skuteczności leczenia zaburzeń wzwodu
Duration of erection: new end-point quantifying efficacy of the treatment of erectile dysfunction

Summary/Abstract: In clinical trials, the efficacy of oral posphodiesterase type 5 (PDE-5) inhibitors in the treatment of erectile dysfunction has traditionally been measured with patient diaries and questionnaires, including International Index of Erectile Function (IIEF), Global Assessment Question (GAQ) and Sexual Encounter Profile (SEP) questions. However, data obtained by these means are based on subjective evaluation and do not provide any information on quantitative aspects of PDE-5 inhibitors efficacy. There is substantial evidence that PDE-5 inhibitors improve penile hardness and maintainance of erection, thus helping patients achieve successful intercourse. However, stopwatch measurements of the actual duration of erection have not been utilized. ENDURANCE is the first PDE-5 inhibitor randomized, placebo controlled stopwatch study that prospectively assessed duration of erection as primary efficacy end-point. It showed that vardenafil (10 mg) produced statistically superior duration of erection leading to successful intercourse compared with placebo. Stopwatch measurement of duration of erection represents a novel, alternative, more objective approach than self-assessment to quantify efficacy of PDE-5 inhibitors. PDE-5 inhibitor – induced prolongation of erection may be of clinical significance.

• Details
• Contents